Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
BCL-w (BCL2L2) is an anti-apoptotic member of the BCL-2 family, promoting cell survival by inhibiting apoptosis. Its unique C-terminal helix regulates access to its BH3-binding groove, modulating interactions with pro-apoptotic proteins. Overexpression of BCL-w is implicated in cancer development and resistance to therapy, making it a potential therapeutic target and biomarker.
Sequestering pro-apoptotic BH3-only proteins; modulation of hydrophobic groove accessibility
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Apoptosis regulator BCL-W (BCL-w).